Back to Search
Start Over
An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer.
- Source :
- Advanced Science; 6/5/2024, Vol. 11 Issue 21, p1-12, 12p
- Publication Year :
- 2024
-
Abstract
- The CRISPR/Cas system has been introduced as an innovative tool for therapy, however achieving specific delivery to the target has been a major challenge. Here, an antibody‐CRISPR/Cas conjugate platform that enables specific delivery and target gene editing in HER2‐positive cancer is introduced. The CRISPR/Cas system by replacing specific residues of Cas9 with an unnatural amino acid is engineered, that can be complexed with a nanocarrier and bioorthogonally functionalized with a monoclonal antibody targeting HER2. The resultant antibody‐conjugated CRISPR/Cas nanocomplexes can be specifically delivered and induce gene editing in HER2‐positive cancer cells in vitro. It is demonstrated that the in vivo delivery of the antibody‐CRISPR/Cas nanocomplexes can effectively disrupt the plk1 gene in HER2‐positive ovarian cancer, resulting in substantial suppression of tumor growth. The current study presents a useful therapeutic platform for antibody‐mediated delivery of CRISPR/Cas for the treatment of various cancers and genetic diseases. [ABSTRACT FROM AUTHOR]
- Subjects :
- GENOME editing
CANCER genes
CRISPRS
OVARIAN cancer
TUMOR growth
MONOCLONAL antibodies
Subjects
Details
- Language :
- English
- ISSN :
- 21983844
- Volume :
- 11
- Issue :
- 21
- Database :
- Complementary Index
- Journal :
- Advanced Science
- Publication Type :
- Academic Journal
- Accession number :
- 177678030
- Full Text :
- https://doi.org/10.1002/advs.202308763